Podcasts about Indiana University Health

Obstructive sleep apnea affects approximately one in four adults and is especially common among patients with neurologic disorders, including stroke, Parkinson disease, dementia, epilepsy, and neuromuscular conditions. In this episode, Dr. Stephanie Stahl discusses why neurologists should routinely screen for OSA, highlights key symptoms and risk factors, reviews important considerations when interpreting sleep studies, and outlines current treatment options beyond CPAP. Learn how recognizing and treating sleep apnea can improve quality of life, optimize management of neurologic disease, and reduce long-term health risks. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Stephanie M. Stahl, MD, FAASM, author of the article "Obstructive Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Stahl is an Associate Professor of Clinical Medicine and Sleep Medicine Fellowship Program Director at Indiana University School of Medicine in Indianapolis, Indiana, where she also serves as Sleep Laboratory Medical Director in the Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine. Additional Resources Read the article: Obstructive Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz  Full episode transcript available here Dr Berkowitz: Obstructive sleep apnea is very common. It can cause or contribute to common neurologic symptoms, such as headache and impaired cognition, and it's a risk factor for stroke. And yet, if you're like me, you may not know too much more about sleep apnea than that. Today, I have the pleasure of talking to sleep expert Dr. Stephanie Stahl to learn what every neurologist should know about OSA.  Dr Jones:  This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr. Aaron Berkowitz. Today I'm interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, Dr. Stahl, and could you please introduce yourself to our audience?  Dr Stahl: Yeah. Thank you for having me. I'm a sleep medicine physician and neurologist and medical director of the Indianapolis Sleep Lab at Indiana University Health. I serve as the director of the Sleep Medicine Fellowship program. I'm faculty advisor for our very first student interest group in sleep medicine at Indiana University School of Medicine. I'm also actively involved in some national leadership roles, including the incoming chair of the American Academy of Sleep Medicine's Education Committee and co-chair of the Academy's Inter-Scorer Reliability Gold Standard Panel. So, I really appreciate this opportunity. I look forward to our discussion.  Dr Berkowitz: Me too, and we appreciate the opportunity too to get to talk to you. You have so much expertise in this area, and I certainly encourage our listeners to look at your article, which is very comprehensive and up to date, and I learned a ton from it. I didn't get much exposure to sleep neurology as a trainee, and I've always worked in academic centers where we have a sleep group and we can refer patients there. So, I have to admit, sleep may probably be the area of neurology I know the least about, and felt like I was learning something new from pretty much every line of your article, and I know our readers will too. So, your article has a lot of excellent detail for our readers on the diagnosis and treatment of this very common condition. But I'd like to keep our interview relatively high level today and focus on the essentials for the practicing general neurologist. So, to start, can you just give us a sense of what obstructive sleep apnea is, and what every neurologist should know about it?  Dr Stahl: Yeah. So obstructive sleep apnea is characterized by either partial or full obstructions in the upper airway. That may sound pretty simple, but this leads to a whole bunch of issues. It leads to oxygen desaturations, arousals from sleep, leading to sleep fragmentation. This can then lead to sympathetic nervous system activation, cerebral hypoperfusion, leading to a whole bunch of symptoms or neurologic conditions.  Dr Berkowitz: Great. And you mentioned this in your article, but just to emphasize, how common is obstructive sleep apnea in the general population?  Dr Stahl: Yeah. So, about a quarter of the general population have obstructive sleep apnea. Much more common in many neurologic conditions.  Dr Berkowitz: Yeah, so very common disorder. We are seeing patients with it quite frequently, whether that's the reason they are seeing us in neurology or not. And this leads to my next question, which is what neurologic symptoms or presenting concerns of a patient should make us think about OSA and the differential diagnosis, and what factors based on the history or the exam or the context would make you suspicious for OSA as the cause of a neurologic symptom? In other words, the patient's presenting with classic symptoms of OSA, and that's why they're seeing a neurologist or seeing a primary care doctor, but is coming for evaluation of, say, headache or other symptoms. And what symptoms would make you think of wanting to consider OSA, and then what aspects of the history or otherwise would make you want to evaluate the patient for OSA?  Dr Stahl: I think a really important takeaway is for neurologists to know that obstructive sleep apnea is very common in neurologic conditions and has that potential to worsen a lot of these conditions or their associated symptoms. And so, it should be on our radar. There are certainly some basic questions and signs and symptoms that we can ask patients about or, or take a look at on exam. And so particular symptoms include snoring. Anybody that snores loudly or frequently, that's a strong risk factor for obstructive sleep apnea. If someone's seeing them stop breathing in their sleep, if they are waking up a lot throughout the night. There are some other symptoms that we may not necessarily attribute upfront to obstructive sleep apnea, such as nocturia, nocturnal reflux, night sweats. There are some daytime symptoms, of course, too, like unrefreshing sleep, daytime sleepiness, morning headaches, an important one in neurology. And then we take a look at the patient's exam. And so, some things that neurologists might want to be thinking about are people with obesity are certainly at a risk for obstructive sleep apnea. But it's also very important to know that someone does not need to have obesity in order to have obstructive sleep apnea. We look at neck size, other morphologic characteristics, such as how much that we can see in the back of their mouth. Can we see their uvula? Does their tongue size appear large in their mouth? And then some other risk factors too, such as male gender, older age, family history, post-menopausal state in women. All that being said, though, sometimes in neurologic conditions, we don't have all of those symptoms or risk factors to be thinking about. And so, in certain neurologic conditions such as stroke where obstructive sleep apnea is very common and has the potential to increase the risk of another stroke, we may need to be thinking about testing these patients even with minimal symptoms or other risk factors.  Dr Berkowitz: That's very helpful. So, you mentioned their headache might be the presenting symptom, right, to a neurologist, and we should certainly be thinking about obstructive sleep apnea as a potential diagnosis, even the cause of the patient's headache, particularly you said patients with morning headache. I often try to think about in patients presenting with, for memory loss, or other cognitive concerns, and that may be due more to inattention from poor sleep, so asking about sleep and symptoms of sleep apnea in those contexts. Are there any other presenting neurologic symptoms not particularly related to sleep? I'm thinking of headache, memory loss, other symptoms that would make you think, "Oh, I should actually screen this patient for sleep apnea also."  Dr Stahl: Yeah, other symptoms to think about in pediatrics, hyperactivity, people that have impaired vigilance, as you alluded to, that poor attention. Sometimes people get misdiagnosed with ADHD, and it's actually just a manifestation of obstructive sleep apnea.  Dr Berkowitz: You alluded to this, Dr. Stahl, that stroke, for example, patients are at higher risk of developing sleep apnea as a result of stroke, and it's also a risk factor for stroke. What other neurologic conditions, primary neurologic diseases, put patients at a higher risk of OSA? And again, similar to the last question I asked you, what are some clues that we should evaluate for? We might be following a patient for their post-stroke care over time and not necessarily thinking about diagnosing a separate condition in them since we're following them for their stroke or their degenerative disease. What are the conditions that put patients at a higher risk of OSA as a result of the condition, and then when would you think about screening them for it?  Dr Stahl: Some particular neurologic conditions where obstructive sleep apnea are very common, in addition to stroke and, and TIA, include Parkinson disease. It can worsen a lot of the motor, cognitive symptoms, sleep disruption that we can see in Parkinson disease. Very common in all causes of dementia, but in particular Alzheimer disease and Lewy body dementia. Very common in neuromuscular conditions. We should definitely have obstructive sleep apnea and all forms of sleep-disordered breathing high on our radar. In conditions like myotonic dystrophy. Charcot-Marie-Tooth is another one where obstructive sleep apnea is very common. Myasthenia gravis, it can worsen the symptoms of that. In particular, a pearl is if somebody has morning weakness in myasthenia gravis, obstructive sleep apnea should be high on your radar. And also, as you mentioned, any forms of headaches. There are some other things too. If somebody has poor seizure control, especially nocturnal seizures, you might have obstructive sleep apnea on your radar as well.  Dr Berkowitz: So, I think you've covered essentially every category of neurologic disease, right? We have cerebrovascular, movement, neurodegenerative, neuromuscular, epilepsy, all conditions where either the disorder itself, such as stroke or the, correct me if I'm wrong, the neurodegenerative disease puts the patient at risk. Or the patient may be at risk for exacerbations of their disease, as you mentioned in myasthenia. I love that pearl. Not fatiguable at the end of the day, but if the patient with myasthenia is telling you they're feeling weaker at the beginning of the day, then think about obstructive sleep apnea and that obstructive sleep apnea worsening control of epilepsy due to poor sleep. So really a lot of bidirectional interactions with this common condition. Okay, so if we're concerned about obstructive sleep apnea, again, myself, a general neurologist speaking perhaps on behalf of other general neurologists, we see a patient with headache or reporting memory loss that we find to be impaired attention, or we see exacerbation of their underlying primary neurologic disease. As you mentioned, we think, "Oh, I've listened to this podcast. I've read Dr. Stahl's article. I should probably be thinking about OSA in this patient, and I should order a sleep study." Now, I admit when I get the sleep study back, I scroll to the bottom, I see they do have obstructive sleep apnea, I'm going to send them over to a sleep specialist. But for the general neurologist, what are some high-yield pearls and some pitfalls to be aware of when we get sleep studies for obstructive sleep apnea, and we are looking at the results? Dr Stahl: The first thing is to understand that there are two main types of sleep studies: in-lab polysomnography and home sleep apnea test. In-lab studies are typically what we consider the more accurate type of study. Main reason for that is that we have EEG, so we can see if someone is awake versus asleep. Most home sleep apnea tests do not utilize EEG, and so when we're looking at respiratory events, apneas or hypopneas, we're looking at over the total recording time rather than the total sleep time. So, we know we're going to capture some time where a person is awake, where we don't have sleep apnea events, and that can be a big amount of time in people with insomnia, poor sleep efficiency. And as a result of that, it can lead to an underestimation of the apnea-hypopnea index. That's really important for people to understand that that means we can end up with a false negative home sleep apnea test, or it can put them in a category of lower severity than what they actually have. And so, if you get a home sleep study report back that's negative for sleep apnea and you remain concerned, you need to go on to do an in-lab study, where about twenty to fifty percent of people will go on to have a positive in-lab study. You can also get false positives with home sleep apnea tests too, and so ideally, we should only be doing home sleep apnea tests in people that are at high risk of having obstructive sleep apnea to decrease our chance of false positive study. When we get that sleep study report, what's important to take a look at? So the main number that we look at currently is the apnea-hypopnea index. The number of apneas, which are full obstructions in that upper airway, or hypopneas, partial obstructions in the upper airway where either there's an oxygen desaturation or an arousal associated with that. Less than five is considered to be normal. Anything five or more gives them a diagnosis of obstructive sleep apnea, and then we stratify them based on the AHI. But it's important to take a look at more than just the apnea-hypopnea index. And while my eyes too on various reports like echocardiograms want to jump to the impression, it is important to take a look at that full report, see what their oxygen levels averaged and what they dipped down to. The arousal index, which is how many times a patient may have woken up briefly throughout the night. Take a look at the histogram, usually an image at the bottom of their report that shows what sleep fragmentation may have been like so that you can take that all in and make that decision. How important are these study findings, and is this a person that would benefit from treatment?  Dr Berkowitz: That's a fantastic overview of sleep studies and some of the highlights to look out for, even if we won't be understanding every detail as you would to know most importantly the caveats about home sleep testing having a fairly high percentage of false negative and false positive results. So being wary if our suspicion is high, and that test is normal or inconclusive to get an in-lab sleep study. And if our suspicion is low or maybe we haven't ordered the test and the patient has had it done elsewhere, and the history doesn't really match up to know that there are false positives on the home studies as well, and again, an in-lab study to settle the diagnosis. Is that right?  Dr Stahl: Yes.  Dr Berkowitz: Okay. Now, for most neurologists, probably if we diagnose OSA, we will be referring the patient to a sleep specialist like yourself for treatment. I think we're all familiar with CPAP and patients being on CPAP. Your article mentions a number of treatment modalities I admit I have not heard of before or maybe heard of in passing, acknowledging most general neurologists are not going to be prescribing or knowing with the nuance that you do as an expert how to decide which treatment a patient would most benefit from or most qualify for. So, can you just give us a broad overview, again, for the general neurologist acknowledging we might see a patient whose past medical history says OSA being treated with fill in the blank. What are the different treatment modalities, and how do you think, just so we can learn from you in broad brush strokes, about particular treatments for particular patients?  Dr Stahl: As you mentioned, most people are familiar with positive airway pressure or PAP therapy, and that does remain our most efficacious treatment. The way I explain it to patients is why PAP therapy is the most effective treatment is it's the only treatment that can take all of the tissues of that upper airway and open them up. Whereas all of our other treatments, we're going to target smaller spaces of that upper airway. So, our first option is if we can get somebody on PAP therapy, we know that that's going to be the best option for the majority. PAP therapy works by basically acting as an air splint to open up the air tissues. Know that masks are not interchangeable. There are masks that cover the nose and go over the nose and mouth and under the nose. Full face masks that cover the nose and mouth, they do typically require higher pressures, also tend to be less comfortable for a lot of patients as well. In addition to different PAP masks, there's different modalities of positive airway pressure therapy too. There are machines that auto-adjust, some that provide fixed pressure, bi-level PAP that provides a higher inspiratory pressure, lower expiratory pressure. Then outside of PAP therapy, there are, as you alluded to, a lot of options and more, continuing to come down the pipeline as well. Mandibular advancement devices or a form of oral appliances has been around for a while. This is device that somebody wears in their mouth. It's preferably customized for their teeth and titratable, meaning that they can make adjustments that pulls their mandible forward in relation to the maxilla in order to pull those tongue tissues further away from the back of the upper airway. That's ideally managed by a qualified sleep dentist or someone that specializes in oral appliance management. Other treatments include surgical options, including hypoglossal nerve stimulation, which is an implanted device that causes the tongue to protrude repetitively throughout their sleep period to hopefully open up the airspace. There's some other surgical options too that open up various places of the upper airway. There's a daytime treatment of obstructive sleep apnea, transoral neuromuscular electrical stimulation that changes the muscle fiber type of the tongue. And then there's some adjunctive treatments that can be helpful too, such as positional therapy, oral facial myofunctional therapy that helps a person breathe better through their nose and may help train the upper airway muscles.  Dr Berkowitz: Great. Well, that's a very helpful overview, and again, I refer our listeners to your article, which talks about all of those modalities in very comprehensive detail. So, Dr. Stahl, as we wrap up our conversation, you have a captive audience of neurologists and neurology trainees here. What would you like to leave us with that every neurologist should know about obstructive sleep apnea?  Dr Stahl: The most important, again, is for neurologists to know that obstructive sleep apnea is so common in your patient population, and it can have a significant negative impact on quality of life and health, including many neurologic conditions. And at the same time, obstructive sleep apnea is very treatable. We have so many options nowadays that we can usually get someone onto adequate treatment. And treatment has that potential to improve several neurologic symptoms and disorders, even at times when you don't think that there's an opportunity to improve symptoms such as say in, headache. So, neurologists really should be screening for signs and symptoms of obstructive sleep apnea, as well as considering testing in high-risk, potentially asymptomatic or minimally symptomatic patients.  Dr Berkowitz: That's a fantastic overview of some of the many pearls that you shared with us today, as well as in your article. So, thank you so much again. Today, I've been interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the August 2026 Continuum issue on neurology of sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today, and thank you again, Dr. Stahl.  Dr Stahl: Thank you again for having me.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026, updating their prior coverage to reflect several recent practice changes.The discussion began with clinical presentation, emphasizing the classic B symptoms—weight loss, night sweats, fatigue, and fever—alongside painless, rapidly enlarging lymphadenopathy. They noted that approximately 30% to 40% of cases present with extranodal involvement (gastrointestinal, central nervous system [CNS], or thyroid) and stressed that an excisional biopsy is required, as fine-needle aspiration cannot preserve the architecture needed for histologic grading.Turning to classification, Drs Armstrong and Tawagi reviewed germinal center vs non-germinal center origin, with non-germinal center disease carrying a worse prognosis. They characterized double-hit lymphoma, triple-hit lymphoma, and double-expressor lymphoma, the last conferring an intermediate prognosis.Regarding workup, they recommended full-body PET scans, laboratory evaluation for tumor lysis syndrome, hepatitis B testing before anti-CD20 therapy, baseline echocardiography before anthracyclines, and lumbar puncture with intrathecal methotrexate in patients at high risk for CNS relapse. They also reviewed updated staging systems.For treatment, they explained that limited-stage disease is now stratified by the stage-modified International Prognostic Index (IPI), guiding abbreviated vs full R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone). In advanced disease, 6 cycles of R-CHOP remains standard, with polatuzumab vedotin-piiq (Polivy) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) now a category 1 regimen for patients with an IPI of 2 or greater. They also addressed dose-adjusted regimens for double-hit disease, CAR T-cell therapy, and bispecific antibodies in the relapsed/refractory setting, as well as surveillance recommendations, cautioning against routine PET imaging.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of data from the phase 3 RASolute 302 trial (NCT06625320), a landmark study presented at the 2026 ASCO Annual Meeting that has established daraxonrasib (RMC-6236) as the new standard of care (SOC) for the second-line treatment of patients with metastatic pancreatic adenocarcinoma.The discussion began by highlighting the historical context of second-line treatment, where standard chemotherapy options like FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin) or gemcitabine-based regimens typically yielded a median overall survival (OS) of only approximately 6 to 7 months. Although RAS mutations drive approximately 90% of pancreatic cancers, they were historically considered undruggable. Daraxonrasib addresses this challenge with its mechanism of action of an oral, RAS(ON), multi-selective, tri-complex inhibitor that targets the active GTP-bound state of both mutant and wild-type RAS, covering variants at codons G12, G13, and Q61.The RASolute 302 trial was an international, open-label study that randomly assigned patients with progression after 1 prior line of therapy to receive either daaxonrasib or investigator's choice of chemotherapy. In the RAS G12–mutated subpopulation of patients, daraxonrasib generated a higher median OS compared with chemotherapy. Similar benefits were observed with daraxonrasib in the overall population, where the median progression-free survival nearly doubled.Drs Armstrong and Tawagi emphasized that the toxicities associated with daraxonrasib are highly clinically relevant and distinct from the myelosuppression seen with chemotherapy. Key adverse effects (AEs) include dermatologic events, diarrhea, and stomatitis. Management of these AEs is critical; the hosts recommended the use of prophylactic oral antibiotics and topical corticosteroids to manage rash, alongside standard oral care for mucositis. Despite being associated with these AEs, daraxonrasib was better tolerated than chemotherapy, with a low treatment discontinuation rate due to AEs.Daraxonrasib is currently accessible in the US through an Expanded Access Program and is undergoing accelerated review for full FDA approval. The experts noted that the agent is being further investigated in the frontline setting through the phase 3 RASolute 303 trial (NCT07491445) and in the adjuvant setting via the phase 3 RASolute-304 trial (NCT07252232), potentially expanding the agent's effect across the continuum of pancreatic cancer care.

In this episode, Tim Pierce, PharmD, MSHA, Administrative Director, Hospital Based Practice Service Lines, Indiana University Health, discusses his transition from pharmacy leadership into hospital administration, the strategic work behind anesthesia recruitment and retention, and how IU Health is building a more sustainable workforce model.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of metastatic urothelial carcinoma management, contrasting historical standards with the rapidly evolving frontline paradigm. As the field transitions into a new era of care, Drs Armstrong and Tawagi emphasized the importance of understanding trial data and toxicity management for both board preparation and clinical practice.The discussion began with details about the historical treatment paradigm, which relied on platinum-based chemotherapy followed by maintenance avelumab for patients who did not progress. However, the experts noted that the current SOC has shifted dramatically following findings from the landmark EV-302 trial, which evaluated the combination of enfortumab vedotin and pembrolizumab.They also explained that the toxicities associated with enfortumab vedotin plus pembrolizumab are highly testable and clinically relevant. Key adverse effects include skin toxicity and peripheral neuropathy, they said. Additionally, the hosts highlighted hyperglycemia and the risk of diabetic ketoacidosis, and emphasized that ocular toxicities, specifically dry eyes, also necessitate referrals to ophthalmology.In the second-line setting following enfortumab vedotin plus pembrolizumab, Drs Armstrong and Tawagi noted that the paradigm unclear, though treatment options include platinum-based chemotherapy or targeted agents. They recommended testing for FGFR mutations to determine patient eligibility for erdafitinib, as well as testing for HER2 expression to determine eligibility for trastuzumab deruxtecan.They also reported that for localized high-grade upper tract urothelial carcinoma, treatment options include neoadjuvant split-dose gemcitabine/cisplatin or upfront surgery followed by adjuvant chemotherapy. In the metastatic setting, they noted that rare disease variants like small cell carcinoma are treated with platinum doublets and immunotherapy, whereas adenocarcinoma management may require FOLFOX.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of localized bladder cancer, covering everything from initial histology to the rapidly evolving treatment paradigms for muscle-invasive disease. Drs Armstrong and Tawagi emphasized that although urothelial carcinoma remains the most common bladder cancer histology, recognizing variants like squamous, adenocarcinoma, and small cell is vital, as they often require surgery-first approaches or specialized chemotherapy. A critical diagnostic pearl highlighted for oncology boards was the necessity of muscularis propria in the transurethral resection of the bladder tumor (TURBT) specimen. If muscle is absent, a repeat TURBT is mandatory to ensure the cancer is not under-staged. For non–muscle-invasive bladder cancer, the treatment goal is preventing recurrence and progression. Patients with high-risk disease should receive BCG induction and maintenance. For those who are BCG unresponsive, Drs Armstrong and Tawagi discussed several novel intravesical therapy options that may be preferred over systemic pembrolizumab to avoid toxicity.The management of muscle-invasive bladder cancer (MIBC) is primarily dictated by cisplatin eligibility, which is determined by performance status, renal function, and the absence of neuropathy or hearing loss. In cisplatin-eligible patients, the phase 3 NIAGARA trial (NCT03732677) results led to a new standard of care (SOC), which is the addition of durvalumab (Imfinzi) to a gemcitabine/cisplatin backbone. Furthermore, the phase 3 KEYNOTE-B15 trial (NCT04700124) data demonstrated that neoadjuvant enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) significantly improved overall survival compared with standard chemotherapy, though this combination is not yet the board-tested standard. For cisplatin-ineligible patients, the phase 3 EV-303 trial (NCT03924895) established neoadjuvant enfortumab vedotin plus pembrolizumab as a new SOC, replacing the previous approach of upfront cystectomy followed by adjuvant nivolumab (Opdivo).Finally, Drs Armstrong and Tawagi discussed trimodal therapy as a bladder-sparing treatment approach. Ideal candidates for this approach must have small tumors, a complete TURBT, no hydronephrosis, and must commit to lifelong cystoscopic surveillance.

In today's episode, we spoke with Misty D. Shields, MD, PhD, about the realities of treating patients with small cell lung cancer (SCLC) in the community setting and how emerging therapies are shaping care delivery. Dr Shields is a translational medical oncologist at Indiana University Health in Indianapolis. In our exclusive interview, Dr Shields highlighted the urgency associated with SCLC treatment, an aggressive malignancy that often presents with rapid symptom onset and widespread metastases. The conversation also underscored the importance of multidisciplinary care. This approach is especially critical in light of expanded treatment options such as chemoimmunotherapy regimens, second-line therapies including tarlatamab-dlle (Imdelltra) and lurbinectedin (Zepzelca), along with clinical trials evaluating antibody-drug conjugates and radioligand therapies.From a practical standpoint, integrating these therapies into the community setting presents logistical challenges. Shields noted that although immunotherapy has been rapidly adopted since its introduction into standard care around 2019, newer agents require additional infrastructure. Education gaps remain another key issue. The growing availability of clinical trials and new treatment strategies makes it essential to guide patients through potential care pathways, helping them understand options across the first-line, maintenance, and relapsed settings.Looking ahead, molecular characterization may play a larger role in shaping treatment strategies. Ongoing research efforts, including cooperative group studies, aim to determine whether these subtypes can guide more personalized treatment approaches in the future. The discussion concluded with a call for continued infrastructure development in community oncology. 

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.In prostate cancer, the phase 3 PEACE-3 trial (NCT02194842) demonstrated a clear overall survival (OS) benefit with the combination of radium-223 and enzalutamide (Xtandi) compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The phase 2 BRCAAway trial (NCT03012321) showed that for patients with mCRPC with BRCA1/2 or ATM mutations, combination therapy with olaparib (Lynparza) and abiraterone led to a longer median progression-free survival (PFS) than sequential treatment. Additionally, the POSEIDON meta-analysis indicated that short-term hormone therapy is adequate for most patients with prostate cancer receiving postoperative radiotherapy, as longer durations did not improve OS.In bladder cancer, the phase 3 KEYNOTE-B15 trial (NCT04700124) showed that neoadjuvant enfortumab vedotin-ejfv (Padcev) combined with pembrolizumab (Keytruda) significantly improved OS and event-free survival vs neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer, despite notable toxicities like skin and ocular adverse effects. Furthermore, the phase 2 RC48G001 trial (NCT04879329) found that disitamab vedotin (RC48) generated responses in patients with metastatic urothelial carcinoma, including those with HER2-low expression.Regarding renal cell carcinoma (RCC), the phase 3 LITESPARK-011 trial (NCT04586231) showed a PFS benefit with belzutifan plus lenvatinib vs cabozantinib in the second-line setting. In the adjuvant setting, the phase 3 LITESPARK-022 study (NCT05239728) demonstrated that adding belzutifan (Welireg) to pembrolizumab improved disease-free survival vs placebo plus pembrolizumab in patients with resected clear cell RCC.Finally, regarding testicular cancer, a phase 2 trial (NCT04876456) of cabozantinib showed meaningful activity in patients with relapsed/refractory germ cell tumors. Drs Armstrong and Tawagi noted that this marks the first nonchemotherapy agent to demonstrate such clinical benefit in this population, providing a new option for patients who have exhausted traditional treatment regimens.

In this episode, James Mladucky, Vice President of Design and Construction at Indiana University Health, shares how the system is building adaptable facilities to support care, research, and education. He discusses leveraging technology, planning large-scale projects, and designing spaces that attract top talent and improve health outcomes across Indiana.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.

Today's episode is about clinical genetic services. In the first segment, Khalida talks to authors Courtney and Jade about retention of patient-facing genetic counselors and how generational age and work environment influence retention. For the second segment, Khalida chats with Dr. Ba-Jaj about telegenetics in India, reviewing data from 3 years and almost 1000 cases!     Segment 1: Factors influencing retention of patient-facing genetic counselors: Role of generational age and work environment Courtney Schroeder, MS, LCGC is an oncology genetic counselor at Indiana University Health. She received her BS in Psychology and Biology from the University of Dayton and her MS in Genetic Counseling from the University of North Carolina Greensboro. Courtney primarily works with the Precision Genomics team at IU Health. She also manages the Hereditary Renal and Prostate Cancer Clinic, which she established through a grant-funded project.   Jade McIntyre, MS, LCGC is a 2025 graduate of Indiana University Genetic Counseling Program. She is currently working as a genetic counselor in the Medical and Molecular Genetics Department at Indiana University Health. Jade is grateful for the opportunity to share the findings from her graduate student research that was published in July 2025.   In this segment we discuss: - This episode explores factors influencing retention of patient-facing genetic counselors. - The study highlights flexibility, autonomy, and experience as key drivers of retention. - Results show higher retention among older, more experienced counselors. - The discussion emphasizes employer strategies to improve workforce retention.   Segment 2: Telegenetics in India: A 3-year review of 938 appointments and patient–clinician perspectives   Dr Shruti Bajaj completed her MBBS and MD Pediatrics from Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai. She subsequently pursued a Fellowship in Clinical Genetics, accredited by Maharashtra University of Health Sciences, from Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai. Thereafter, Dr. Shruti Bajaj amassed vast clinical experience as an Assistant Professor in the busy Department of Pediatrics and Clinical Genetics at Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, for five years (2013- 2017). She has to her credit a short observership and training in Clinical & Laboratory Genetics from Kasturba Medical College, Manipal. She has additionally been trained through multiple short modules in different subspecialities of Clinical Genetics from prestigious centres across the country and the world. Some of these include the 'Cancer genetic counseling' course from Tata Memorial Hospital, Mumbai and the challenging 'Skeletal dysplasia' course from Lausanne, Switzerland. Dr Shruti Bajaj is the Founder and Director of The Purple Gene Clinic, which she established in 2017. The Purple Gene Clinic provides cares to patients across the country, and is one of the busiest and most trustworthy Genetic Clinics in India. Despite a demanding and busy practice, Dr Shruti Bajaj obtained the prestigious International Masters Degree in Neurometabolism and Cell Biology, from SJD Barcelona's Children Hospital, University of Barcelona, in 2024. During this course, Dr. Bajaj was awarded the prestigious International Travel Scholarship for both 2023 and 2024, after her submitted clinical cases were selected as the best amongst all applications, highlighting her exceptional clinical acumen and dedication. As a testimony to her passion for academics, Dr Bajaj has numerous national and international publications, as well as chapters in leading textbooks, to her credit. Dr Bajaj's innate compassion and passion for social services led her to establish a support group for individuals with Down syndrome, called PEHEL, in Mumbai in 2018. She also runs a charitable OPD at The Purple Gene Clinic, called Shantidevi Gupta Charitable OPD, in the loving memory of her late grandmother. Social media handles: Linkedin profile name: Dr Shruti Bajaj (Agarwal)  In this segment we discuss: - How tele-genetics improves access to genetic care across India. - When pure vs hybrid telemedicine works best for diagnosis. - Patient cost and time savings alongside clinician-reported challenges. - Scalable lessons for implementing tele-genetics in resource-limited settings.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

In this episode, Denzil Ross, MBA, FACHE, President of the South Region at Indiana University Health, shares how redesigned patient flow reduced emergency department hold times by 30 percent while supporting cardiovascular growth. He also outlines 2026 priorities around access to care, graduate medical education expansion, and strategic program growth amid industry uncertainty.

This episode, recorded live at the Becker's 13th Annual CEO + CFO Roundtable, features Kelley Wells, Rph VP- Clinical Applications, Indiana University Health, as she discusses IU Health's rapid growth and major capital projects. She shares insights on leading a large scale Epic conversion, building smart hospitals, and preparing clinical IT teams to support future innovation.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to highlight chronic lymphocytic leukemia (CLL) updates from the 2025 ASH Annual Meeting. Drs Armstrong and Tawagi noted that CLL is typically diagnosed in asymptomatic, elderly individuals presenting with lymphocytosis. A definitive diagnosis is established by confirming the clonality of circulating B lymphocytes via immunoglobulin light chain restriction on flow cytometry, they explained. Treatment initiation is reserved for active disease, which is indicated by B symptoms, progressive cytopenias, threatened organ function, or bulky disease such as splenomegaly, they said. They continued by reporting several prognostic features that denote poor outcomes. Current standard frontline regimens use covalent BTK inhibitors or time-limited targeted regimens that include venetoclax (Venclexta), often combined with an anti-CD20 monoclonal antibody, according to the experts. They added that TKI-based therapy is preferred for patients with high-risk features. The phase 3 BRUIN CLL-313 trial (NCT05023980) investigated pirtobrutinib (Jaypirca), a highly selective noncovalent BTK inhibitor, compared with bendamustine and rituximab (BR) in patients with treatment-naive CLL. The trial showed a significant improvement in progression-free survival with pirtobrutinib vs BR. Pirtobrutinib was also associated with a favorable safety profile, with modest rates of class-associated toxicities, including all-grade bleeding, arthralgia, and atrial fibrillation. Although pirtobrutinib showed superior efficacy in BRUIN CLL-313, the clinical interpretation of these data is complicated because BR is an outdated control arm compared with contemporary frontline standards, Armstrong and Tawagi emphasized. Furthermore, the requirement for indefinite therapy with BTK inhibitors is a sequencing challenge, particularly as pirtobrutinib is currently approved in the post-covalent BTK inhibitor setting, they continued. However, its favorable toxicity profile suggests potential utility in elderly patients with pre-existing cardiovascular comorbidities, they noted. Future studies are focused on comparing pirtobrutinib vs time-limited venetoclax and evaluating various triplet regimens, they concluded.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to review exciting updates from the 2025 ESMO Congress about bladder cancer management that have the potential to change guidelines. In non–muscle-invasive bladder cancer (NMIBC), 2 trials added immunotherapy to BCG. The phase 3 POTOMAC trial (NCT03528694) combining durvalumab (Imfinzi) with BCG for high-risk, BCG-naive NMIBC was positive, demonstrating improved disease-free survival with the combination. This regimen might become a new standard of care and could reduce the need for early radical cystectomy, the experts highlighted. For muscle-invasive bladder cancer, the phase 3 KEYNOTE-905 study (NCT03924895) combined perioperative enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) for cisplatin-ineligible patients. This positive trial demonstrated strong event-free survival and overall survival (OS) with the combination. Furthermore, the phase 3 IMvigor011 trial (NCT04660344) provided data on a risk-adapted approach using adjuvant atezolizumab (Tecentriq) for post-cystectomy patients with circulating tumor DNA (ctDNA)–positive disease. For these patients, atezolizumab generated benefits in disease-free survival and OS, supporting the future use of ctDNA for personalized therapy. Updates in metastatic bladder cancer emphasized the importance of testing for FGFR alterations and HER2 expression in the second-line setting, Armstrong and Tawagi explained. The phase 1 FORAGER-1 study (NCT05614739) showed the efficacy of an oral FGFR3 inhibitor in heavily pretreated patients and showed lower rates of hypophosphatemia with the agent compared with erdafitinib (Balversa). Overall, the conference yielded many new and exciting data points for the treatment of patients with bladder cancer.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a comprehensive review of the current management of metastatic breast cancer, emphasizing evidence-based treatment strategies across molecular subtypes, toxicity management, and patient-centered care. Drs Armstrong and Tawagi discussed that the primary goals of metastatic breast cancer therapy include prolonging survival, controlling symptoms, minimizing toxicity, improving quality of life, and incorporating patients' goals and preferences into care decisions. Their discussion also highlighted the importance of recognizing when transitioning to best supportive care is most appropriate. For estrogen receptor–positive metastatic breast cancer, they noted that first-line therapy includes an aromatase inhibitor or fulvestrant (Faslodex) combined with a CDK4/6 inhibitor, with ovarian function suppression for premenopausal patients. PARP inhibitors are recommended for patients with BRCA1/2-positive disease. In visceral crisis, chemotherapy remains the category 1 recommendation. Second-line treatment options include therapies guided by repeat molecular testing. fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) is approved for patients with HER2-low disease. For HER2-positive metastatic breast cancer, first-line treatment consists of a taxane plus pertuzumab (Perjeta) and trastuzumab (Herceptin), followed by T-DXd in the second-line setting. For triple-negative metastatic breast cancer, therapy depends on PD-L1 status. The episode concluded by underscoring the role of bone-protective agents such as zoledronic acid, pamidronate, or denosumab (with dental clearance to prevent osteonecrosis). Key takeaways emphasize tailoring therapy to molecular subtype, recognizing drug-specific toxicities, and prioritizing patient-centered decision-making in the management of metastatic breast cancer.

About two years ago, Indiana University Health implemented a 340B-funded comprehensive medication review clinic after pharmacy staff noticed patients at their hospitals were not filling maintenance prescriptions due to high cost. Although patient assistance was available, there was not a systematic approach to connecting qualifying patients with the financial help and education they needed, and the health system started the clinic to fill that gap. IU Health Regional Pharmacy Manager of Ambulatory Services Carrie Krekeler discusses how the clinic came about and how it works to improve patient health outcomes.Improved Drug Affordability and Patient EducationWhen a prescription goes through IU Health's comprehensive medication review clinic, pharmacists and other staff will prioritize finding financial assistance for eligible individuals and teaching patients important information about taking their medications. Krekeler says clinic staff will look for discounts for all medications a patient is on and see what a patient's insurance will cover, if there are copays, and if prior authorization is needed. Staff then will connect patients to coupon cards, manufacturer assistance programs, or 340B-funded assistance through IU Health.Demonstrated ResultsIn the two years since the clinic launched, Krekeler says its success has prompted IU Health to reinvest more 340B dollars to expand its reach. Patients with heart failure and diabetes who have gone through the clinic have seen significant improvements in their key health metrics. The clinic helps patients better maintain their health and stay out of the hospital.Understanding 340B Is Vital for Such ProgramsKrekeler says IU Health was able to launch its clinic after adapting a similar initiative that UC Davis had implemented. The key to getting the IU Health clinic off the ground was obtaining buy-in from executives who understood 340B and finance and were able to see the long-term benefit in investing 340B dollars in this area.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to feature a conversation about soft tissue sarcoma management. Drs Armstrong and Tawagi discussed that soft tissue sarcomas represent a rare and heterogeneous group of malignancies that arise from mesenchymal cells rather than epithelial cells and encompass several distinct histologic subtypes. They explained that although uncommon, these sarcomas are frequently emphasized in board examinations, partly because their management has historically been stable, though recent FDA approvals and ongoing research have expanded therapeutic options. They noted that risk factors may include prior radiation exposure, environmental agents, and viral infections. Additionally, they shared that chronic lymphedema is associated with angiosarcoma, whereas rare hereditary syndromes may predispose individuals to specific sarcoma subtypes.  Clinically, they explained that sarcomas may arise anywhere in the body, though many occur in the thigh, buttocks, or groin, typically presenting as painless, enlarging masses often mistaken for benign lesions. They emphasized that diagnosis requires core needle biopsy to preserve tissue architecture and that staging relies on MRI of the primary site and CT of the chest, given the strong predilection for pulmonary metastases. They also summarized the five subtypes of soft tissue sarcoma—synovial, clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid. They reported that the cornerstone of localized disease management is surgical resection, preferably limb-sparing when feasible, combined with radiation for larger or high-risk tumors. They also highlighted novel strategies like immunotherapy. For metastatic disease, they stated that surgical resection of pulmonary metastases can achieve durable remissions in select patients. 

In this episode of The Wisdom Of... Show, host Simon Bowen speaks with Trevor Yager, founder and chairman of TrendyMinds, who built a 30-year digital marketing empire by systematically doing the opposite of what every other agency owner does. Drawing on his background in psychology and decades-long relationships, Trevor offers powerful insights into values-driven leadership, transparent business practices, and what it really takes to build sustainable competitive advantages . Discover how prioritizing relationships over revenue creates the strongest foundation for long-term business success.Ready to elevate your strategic thinking? Join Simon's exclusive masterclass on The Models Method. Learn how to think systemically about complex business challenges: https://thesimonbowen.com/masterclassEpisode Breakdown00:00 Introduction and the unconventional path from psychology to digital marketing empire05:28 The college decision and why human behavior became a business advantage12:43 Early mistakes and how owning them became a competitive strategy18:47 Building TrendyMinds from screenprinting to digital transformation25:19 The transparency strategy that "shouldn't have worked" during acquisition discussions32:14 How to avoid becoming a dinosaur while staying true to core principles38:56 The ideation advantage and why creativity matters more than tools in the AI era45:23 Long-term relationship building versus short-term revenue optimization52:37 Values-driven decision making and the State of the Union invitation58:44 The anti-agency playbook and systematic disruption through principled leadershipAbout Trevor YagerTrevor Yager is the founder and chairman of TrendyMinds, a leading digital marketing agency he started as a college student in 1995. Under his leadership, TrendyMinds has grown from a small startup into a full-service agency trusted by global enterprise clients, including Salesforce, Eli Lilly, Indiana University Health, and Cummins.Now serving as Chairman, Trevor guides the strategic vision and growth of the company while investing in startups, commercial real estate, and new ventures. His work has earned multiple Inc. 5000 listings and industry recognition for campaigns that genuinely improve lives.With a background in psychology, history, and political science, Trevor brings a unique human-centered perspective to business strategy and relationship building. He represents a values-driven approach to entrepreneurship that prioritizes long-term sustainable growth over short-term profits.Based in Indianapolis, Indiana, Trevor continues to mentor emerging entrepreneurs while overseeing strategic acquisitions and investments across multiple industries.Connect with Trevor YagerLinkedIn: https://www.linkedin.com/in/trevoryager/Website: https://trendyminds.com/aboutInstagram: https://www.instagram.com/trendyminds/p/C02YU0jvGEi/Facebook: https://www.facebook.com/TrevorYager/Twitter:...

Dr. Russell Ledet, M.D., Ph.D., M.B.A., shares his remarkable journey from digging through dumpsters as a child to becoming a triple board resident at IU Health. In this powerful episode of The Freedom Forum, host Angela B. Freeman explores how Dr. Ledet's time in the U.S. Navy, his experience at an HBCU, and his pursuit of advanced education shaped his commitment to leadership, equity and service. He discusses founding The 15 White Coats, fostering culturally relevant literacy, launching Reels and Roots, and developing an AI-powered mental health app to bridge communication between parents and teens. Dr. Ledet also reflects on how Indiana can build a more inclusive future in healthcare leadership.

Inside INdiana Business Radio for the afternoon of July 21, 2025. A Fort Wayne-based orthopedic startup is preparing to kick off a clinical study for a unique innovation. The next stage of the Ohio River Crossing project in southwest Indiana is getting underway. Plus, Indiana University Health is rethinking patient room design with its new downtown Indianapolis hospital. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN trial (NCT04592913), which were presented at the 2025 ASCO Annual Meeting. MATTERHORN was a randomized, double-blind, multinational study evaluating the addition of durvalumab (Imfinzi) to FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with previously untreated, resectable gastric or gastroesophageal junction adenocarcinoma. In the MATTERHORN trial, 948 patients were randomly assigned 1:1 to receive either durvalumab or placebo in combination with perioperative FLOT, followed by 10 cycles of durvalumab or placebo as adjuvant therapy. The primary end point was event-free survival (EFS); secondary end points included overall survival (OS) and pathological complete response (pCR). The trial met its primary end point. Durvalumab plus FLOT (n = 474) significantly improved EFS vs placebo plus FLOT (n = 474; HR, 0.71; 95% CI, 0.58-0.86; P < .001), representing a 29% reduction in risk of progression, recurrence, or death. The interim OS analysis showed a nonsignificant trend favoring durvalumab (HR, 0.78; 95% CI, 0.62-0.97; P = .025). The pCR rate was 19% (95% CI, 15.75%-23.04%) with durvalumab vs 7.2% (95% CI, 5.02%-9.88%) with placebo. Toxicity profiles were comparable between the 2 groups, though immune-related adverse effects were more frequent with durvalumab. Importantly, the addition of durvalumab did not delay surgery or initiation of adjuvant therapy. Although the MATTERHORN regimen is not yet FDA approved or included in the National Comprehensive Cancer Network guidelines, this trial demonstrates a promising EFS benefit and potential practice-changing implications, pending mature OS data and further molecular subgroup analyses, according to Armstrong and Tawagi.

In this moving episode of It Takes Balls, Andrew Kettner shares his powerful story of battling primary mediastinal non-seminomatous germ cell cancer (PMNSGCT), a rare and aggressive form of testicular cancer that showed up not in his testicles, but in his chest.Andrew opens up about the subtle symptoms he first noticed: shortness of breath, fatigue, and elevated heart rate - symptoms he initially wrote off as “just getting older.” But after a gut instinct sent him to the ER, a chest X-ray revealed a massive tumor near his heart. Thanks to the quick thinking of oncologist Dr. Sean Kern, who recognized elevated tumor markers, Andrew was spared unnecessary surgery and given a critical diagnosis: testicular cancer.With a prognosis of only 40–50% survival at two years, Andrew began a grueling VIP chemotherapy regimen, complicated by a blood clot and extreme side effects including weight loss and neuropathy. He credits his survival not only to expert care at Walter Reed and Indiana University Health but also to the unshakable support of his wife, children, and medical team.The episode also explores what survivorship looks like as a military leader and father. Andrew reflects on the emotional toll of treatment, the way it reshaped his priorities, and how he's teaching his sons to check themselves monthly for early signs of testicular cancer. Now with no evidence of disease, he's using his experience to raise awareness within the military community, where he believes testicular cancer is underrecognized.If you're navigating an advanced testicular cancer diagnosis, are a member of the armed forces, or simply want to hear an honest, grounded survivor story, this episode is packed with insight, emotion, and inspiration from someone who faced long odds.Join The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Andrew:https://www.facebook.com/profile.php?id=70000153Theme song: No Time Like Now - Tom Willner www.tomwillner.com

What does it take to turn pharmacy into a revenue generator—while keeping patient care at the heart of every decision? On this episode of Power Supply, we welcome Derek Imars, Executive Director-Pharmacy Supply Chain at Indiana University Health, to explore his "Purchase to Patient" philosophy and the five-year roadmap driving his team's transformation. From tackling critical drug shortages to optimizing centralized service centers, Derek shares how his team is building a smarter, more connected pharmacy supply chain. Whether you're a pharmacy leader seeking operational improvements or a supply chain professional curious about pharmaceutical complexities, this episode offers practical insights into building specialized pharmacy supply chain strategies! Once you complete the interview, jump on over to the link below to take a short quiz and download your CEC certificate for 0.5 CECs! – https://www.flexiquiz.com/SC/N/ps14-05 #PowerSupply #Podcast #AHRMM #HealthcareSupplyChain #PharmacySupplyChain #PharmacyOperations #CostSavings #Revenue

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

You may have become so used to them that you no longer notice, but snaking through downtown Indianapolis' northwest quadrant are the remains of a revolutionary public transit system that transported riders on elevated tracks 30-feet high. It was called the People Mover, developed for $44 million by Clarian Health Partners, the hospital system now known as Indiana University Health. From its launch in 2003 to 2019, it recorded roughly 6 million rider trips on a 1.4-mile track running between Methodist Hospital, University Hospital and Riley Hospital for Children.  The People Mover had the cooperation of city officials, who allowed the track to use public right of way along Senate Avenue, West 11th Street and University Boulevard. And the People Mover was filled with promise, as some predicted it could be expanded to a larger public transit system that would include Indianapolis International Airport. But tram came to screeching halt in 2019, when IU Health said it would begin offering shuttle buses instead and expected to save about $40 million over 10 years. That also was about the time IU Health began planning a massive facility consolidation and modernization project downtown. IBJ reporter Daniel Lee has a personal connection to the People Mover and recently began looking into what remains of the twin-track system and whether IU Health has any plans to resurrect it. In this week's edition of the IBJ Podcast, Lee also gauges support for a proposal that would transform the infrastructure into an elevated trail celebrating the heritage of Black communities on downtown's northwest side.

This week's IBJ Podcast features a conversation from our Forty Under 40 awards breakfast last week with Maureen Weber, the winner of this year's Alumni Award.  Maureen was originally a Forty Under 40 honoree in 2010. Back then, she had just finished reorganizing the Indiana Department of Education and had taken a job as director of community outreach and engagement at Clarian Health, now Indiana University Health. Sixteen years later, Maureen is president and CEO of Early Learning Indiana. She said she took the job because she saw the opportunity to transform the lives of young children, especially vulnerable ones. IBJ Editor Lesley Weidenbener talked with Maureen on stage about the work Early Learning Indiana is doing today and about leadership and learning from failure. You can read more about Maureen and see our latest Forty Under 40 class here.

High phosphorus (hyperphosphatemia) is a common complication caused by chronic kidney disease. Join us for this NKF Live to learn more about why this happens and how to successfully manage high phosphorus in CKD. During this program, you will hear a kidney doctor, a clinical pharmacist, and a person living with high phosphorus discuss important information to know about when managing high phosphorus.   Dr. Jay Wish is Professor of Clinical Medicine at Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Outpatient Dialysis at Indiana University Health.  He is past president of the National Forum of ESRD Networks, served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of the latter's Visionary Award in 2005. He has over 150 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management and vascular access. Dr. Katie Cardone is an associate professor at Albany College of Pharmacy and Health Sciences in Albany, NY. She is a clinical pharmacist with a clinical practice and research program focused on improving care in patients with kidney disease in outpatient nephrology and dialysis. She co-led the publication of pharmacy practice standards for pharmacists caring for people with kidney disease. She is a member of the Board of Pharmacy Specialties Ambulatory Care Pharmacy Council and is a fellow of the National Kidney Foundation, the American Society of Nephrology, and the American College of Clinical Pharmacy. Quenton Turner Gee has been on in-center hemodialysis for about 2 years. He was diagnosed with Stage 4 CKD in 2020. After a battle with COVID-19, it quickly progressed to end-stage kidney disease. Since starting on dialysis, he's been advocating for mental health and policies improving access to transplants and kidney innovations.   Additional Resources: Phosphate Lowering Agents High Phosphorus Information NKF Peers   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Today's guests are Lena N. Wilson, MHI, RHIA, CCS, CCDS, CDI manager at Indiana University Health in Indianapolis, and A.J. Hegg, MD, CCDS, medical director of UM at Essentia Health in Duluth, Minnesota. Today's show is part of the “Talking CDI” series, hosted by ACDIS Director Rebecca Hendren, and it kicks off an occasional series featuring members of the ACDIS Advisory Board. Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. Want to submit a question for a future "listener questions" episode? Fill out this brief form!  CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEU which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEU, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Free Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: https://acdis.org/acdis-podcast/acdis-advisory-board-series-second-level-reviews) Note: To ensure your certificate reaches you and does not get trapped in your organization's spam filters, please use a personal email address when completing the CEU evaluation form. The cut-off for today's episode CEU is Monday, January 6, 2025, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEU for this week's episode. Note that the CEU period has been extended for this week's episode due to the New Years holiday. Today's sponsor: Today's show is brought to you by the 2025 ACDIS conference, taking place May 4-7, in Orlando, Florida. Learn more and register here: https://bit.ly/47erPfl ACDIS update: ACDIS members can download the new January/February edition of the CDI Journal, focused on “Your Career in CDI,” now! (https://bit.ly/3VzphDP) Apply to serve on an ACDIS committee by January 31, 2025! (https://www.surveymonkey.com/r/January-2025-Committees) Learn more about the 2025 ACDIS national conference and register today! (https://bit.ly/47erPfl)

In this episode, Jenn Alvey, CFO of Indiana University Health, joins the podcast to discuss key trends shaping healthcare, including labor shortages, inflationary pressures, and the transformative potential of AI. She also highlights IU Health's innovative affordability plan and ambitious growth initiatives, providing valuable perspectives on how the organization is expanding and enhancing care for Indiana's communities.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a curated list of resources to use as you study for the hematology and oncology board exams. Drs Armstrong and Tawagi discussed their personal board review plans they followed in the months leading up to boards, including the books, sections of the National Comprehensive Cancer Network Guidelines, videos, question banks, and podcasts; where you can find the “cheat sheets” they made to help them study; and the importance of personalizing your study plan based on your own knowledge and strengths. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Target has launched a collection designed by 'fur-fluencers' to attract pet owners, along with reality TV-styled social content and national ads featuring mascot Bullseye. PayPal's new ad campaign stars Will Ferrell and emphasizes the use of PayPal for both in-store and online transactions. Old Navy is celebrating its 30th anniversary with a '90s-inspired collection and campaign. JC Penney's football-themed campaign includes weekly deals promoted by celebrities like Shaquille O'Neal. Walmart is using Fubo's takeover ad format to connect content and commerce in a CTV environment, highlighting the importance of digital accessibility, the impact of generative AI on marketing strategies, and the evolution of in-store retail media.Steward Health Care has been auctioning off assets, with 15 hospitals transitioning to interim managers and the sale of its Arkansas facility. A data breach at a CMS contractor could affect over 946,000 Medicare beneficiaries. PBM executives have declined to revise controversial testimony given to a House committee. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Medicare Advantage bonuses are expected to drop for the first time since 2015. Payers are exploring ways to improve the quality of provider data through technology.J&J led a $50 million financing round for imaging company SpectraWave, which will support commercial expansion and product additions for their system used in treating coronary artery disease. Apple announced a new sleep apnea feature for its smartwatch, while Roche is set to launch a new continuous glucose monitoring system in Europe. The FDA has found that many AI devices lack validation data, with only 28% being tested prospectively. Singapore is seen as an ideal hub for medtech companies looking to expand in Southeast Asia.A new lung cancer drug developed by Summit has shown a "striking" benefit over Keytruda in a detailed study, confirming earlier claims by the company. The positive results led to a significant increase in shares. In other news, three biotechs raised $700 million in IPOs, the House backed a bill restricting China's role in US biotech, and Centessa's sleepiness drug showed promising results.The Senate is expected to hold Steward CEO Ralph de la Torre in contempt for failing to appear before a subcommittee. In other news, Elevance is acquiring Indiana University Health's insurance business, and Steward Health Care has sold some assets and transitioned hospitals to interim managers. Abortion laws are changing in the US, with North Dakota overturning a near-total ban. California's data exchange framework is proving successful in improving health equity and streamlining information.Three biotechs, Bicara Therapeutics, Zenas Biopharma, and MBX Biosciences, raised $700 million in IPOs, marking the busiest week for biotech stock sales since February. Biotech IPOs are considered the industry's lifeblood, providing insight into mature startups waiting to test public markets. Moderna admitted during an investor presentation that they were overly optimistic about their RSV vaccine's market share potential compared to rivals GSK and Pfizer. Roche's subcutaneous Tecentriq received FDA approval, beating competitors Merck and Bristol Myers to market. Additionally, Gilead's shot succeeded in its second HIV trial.Biopharma Dive provides in-depth journalism and insight into trends shaping biotech and pharma, covering topics from clinical readouts to FDA approvals, gene therapy, drug pricing, and research partnerships. Subscribe to Biopharma Dive for daily news and insights in the industry.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a review session for the oncology board exams. Drs Armstrong and Tawagi discussed high-yield oncology and hematology topics to focus on during study sessions, memorization tricks they used for their own boards, and other tips for exam preparation.

In this week's episode, we're joined by Jeremy Rogers, Executive Director of Digital Marketing and Experience at Indiana University Health, who brings nearly nine years of experience at the organization and a deep understanding of the evolving healthcare marketing landscape. We dive into a critical challenge many marketers face today: demand for healthcare services now far exceeds supply, requiring a strategic shift.   Key Discussion Points: ●       Evolving Marketing Priorities: Marketing's traditional focus on acquiring new patients has evolved due to longer wait times for patients. Marketers now need to manage patient expectations and maintain strong relationships throughout the patient journey. ●       Redefining the Marketer's Role: Today, marketers must continuously reassess their role and be the voice of the patient within their organizations. This means advocating for patient needs and adjusting messaging and tactics to align with new realities. ●       Building Internal Relationships: Successful marketers work closely with operations, scheduling, and other internal teams to optimize every touchpoint along the patient journey—from appointment scheduling to post-care follow-up. ●       Navigating Hybrid Work: Balancing in-person and remote work is essential for building strong internal relationships, especially with leaders and operational teams who are often on-site. ●       Data-Driven Strategies for High Demand: Understanding access metrics and focusing on areas where patient care can be optimized is key to navigating the current challenges.   Connect with Jeremy: ●  LinkedIn:https://www.linkedin.com/in/jeremyrogers/               Connect with Jenny: ●   Email: jenny@hedyandhopp.com ●   LinkedIn: https://www.linkedin.com/in/jennybristow/   If you enjoyed this episode we'd love to hear your feedback! Please consider leaving us a review on your preferred listening platform and sharing it with others.

Katie Du Fresne discusses her journey from being a nurse to being a risk manager and her time working as a risk management consultant. She'll also elaborate on her position as the Executive Director of Clinical Risk Management for Indiana University Health.

Venture with us as we uncover the profound stories and strategies behind the success of healthcare luminary Denzil Ross, President of the South Central Region at Indiana University Health, whose journey from the idyllic shores of Trinidad and Tobago to the bustling corridors of Midwest healthcare institutions embodies innovation and leadership. Denzil shares his experiences with advanced technologies and lean methodologies that are reshaping patient care delivery. This episode not only traces Denzil's inspiring ascent but also delves into the vital role of executive presence and the conscious development of diverse leadership teams that echo the multifaceted communities they serve.If you're fascinated by the fusion of healthcare and technology, you'll find Denzil's insights on the transition from paper to electronic medical records and the burgeoning role of AI in healthcare nothing short of revelatory. His technical prowess has been crucial in navigating these monumental shifts, serving as a testament to the power of bridging the gap between the languages of healthcare and technology. The conversation extends to the impact of diversity in leadership, emphasizing how varied perspectives and backgrounds can drive innovation and adaptability in the complex arena of healthcare.Finally, we spotlight the significance of leadership development programs, such as the Elevate cohort and the Leverage Network fellowship, in cultivating the next echelon of Black healthcare leaders. Denzil recounts the intrinsic value of mentorship and strategic networking, underscoring how these programs shape professionals who are not just ready to lead but poised to transform the industry. As we wrap up, we extend an invitation to join the burgeoning community and continue the conversation at the upcoming National Association of Health Services Executives event, promising a beacon of support and enrichment for minority leaders in healthcare.Thanks for tuning in to this episode of Follow The Brand! We hope you enjoyed learning about the latest marketing trends and strategies in Personal Branding, Business and Career Development, Financial Empowerment, Technology Innovation, and Executive Presence. To keep up with the latest insights and updates from us, be sure to follow us at 5starbdm.com. See you next time on Follow The Brand!

IU Health's CEO on Prioritizing Consumer Experience Season 10 kicks off with Dennis Murphy, President and CEO of Indiana University Health. Dennis shares what senior hospital leaders can do to keep making progress with consumer experience when they have so many other priorities, then he provides some details about an exciting new hospital that IU Health is developing in downtown Indianapolis and how patient experience is being prioritized as part of the building.  All that, plus the Flava of the Week about Kroger piloting new primary care clinics for seniors. What's Kroger's formula for success among underserved Medicare populations, and how can grocery brands play a greater role in consumers' health and wellness?  Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Season 10 kicks off with Dennis Murphy, President and CEO of Indiana University Health. Dennis shares what senior hospital leaders can do to keep making progress with consumer experience when they have so many other priorities, then he provides some details about an exciting new hospital that IU Health is developing in downtown Indianapolis and how patient experience is being prioritized as part of the building.  All that, plus the Flava of the Week about Kroger piloting new primary care clinics for seniors. What's Kroger's formula for success among underserved Medicare populations, and how can grocery brands play a greater role in consumers' health and wellness?  This show is produced by Shift Forward Health, the consumer advisory firm that partners with you to operationalize consumer-first health. (#302) See omnystudio.com/listener for privacy information.

Supporters of the world-famous Kinsey sex research institute continue to protest Indiana University's plan to separate it from the university. A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug. New funding from Indiana University Health aims to improve health outcomes for Hoosiers in need. Both the Indiana Democratic and Republican parties had reasons to celebrate Tuesday's election results. Children with disabilities are entitled to a public education, but when schools don't fulfill that obligation, it's often left to parents to fight for their rights under federal law. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily.  Subscribe to WFYI News Now wherever you get your podcasts. Today's episode of WFYI News Now was produced by Darian Benson, Abriana Herron, and Kendall Antron with support from Sarah Neal-Estes.

Why Marketers Must Evangelize For Consumers Jared welcomes Jeremy Rogers, Executive Director of Digital Marketing and Experience at Indiana University Health. Jeremy describes what it takes to evangelize for consumer transformation and highlights ways that he sees hospitals innovating in their marketing.  All that, plus the Flava of the Week about Amazon Clinic's nationwide rollout. What does Amazon's moves signal to us about opportunities for more consumer-centered health experiences, and should we be rooting for anyone who makes it easier, less scary, and less costly to have our health and wellness needs met?  Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Jared welcomes Jeremy Rogers, Executive Director of Digital Marketing and Experience at Indiana University Health. Jeremy describes what it takes to evangelize for consumer transformation and highlights ways that he sees hospitals innovating in their marketing.  All that, plus the Flava of the Week about Amazon Clinic's nationwide rollout. What does Amazon's moves signal to us about opportunities for more consumer-centered health experiences, and should we be rooting for anyone who makes it easier, less scary, and less costly to have our health and wellness needs met?  This show is produced by Shift Forward Health, the channel for change makers. Subscribe to Shift Forward Health on your favorite podcast app, and you'll be subscribed to our entire library of shows. See our full lineup at ShiftForwardHealth.com. One subscription, all the podcasts you need, all for free. (#281)See omnystudio.com/listener for privacy information.

Today's guest is Lena Wilson, MHI, RHIA, CCS, CCDS, the manager of CDI and ICD-10 clinical education at Indiana University Health in Indianapolis. Today's show is part of the “Leadership with Linnea” series. In every episode of this series, ACDIS Associate Editorial Director Linnea Archibald is joined by one guest from the ACDIS Leadership Council ranks or a contributor from one of our ACDIS publications to discuss a topic relevant to leaders in the industry, whether or not they currently hold a traditional management title. Last year, the ACDIS Advisory Board published a white paper on the topic of CDI and case mix index, which can be found here. (https://ow.ly/oflc50P8yfu) Our intro and outro music for the ACDIS Podcast is “medianoche” by Dee Yan-Kay and our ad music is “Take Me Higher” by Jahzzar, both obtained from the Free Music Archive. Have questions about today's show or ideas for a future episode? Contact the ACDIS team at info@acdis.org. CEU info: Each ACDIS Podcast episode now offers 0.5 ACDIS CEUs which can be used toward recertifying your CCDS or CCDS-O credential for those who listen to the show in the first two days from the time of publication. To receive your 0.5 CEUs, go to the show page on acdis.org, by clicking on the “ACDIS Podcast” link located under the “Resources” tab. To take the evaluation, click the most recent episode from the list on the podcast homepage, view the podcast recording at the bottom of that show page, and click the live link at the very end after the music has ended. Your certificate will be automatically emailed to you upon submitting the brief evaluation. (Note: If you are listening via a podcast app, click this link to go directly to the show page on acdis.org: https://acdis.org/acdis-podcast/cdi-and-case-mix-index-problem) The cut-off for today's episode CEU is Friday, July 21, at 11:00 p.m. eastern. After that point, the CEU period will close, and you will not be eligible for the 0.5 CEUs for this week's episode. Today's sponsor: ACDIS is proud to offer a new certificate program for CDI leaders and those looking to grow into a leadership role. Earn your certificate in CDI leadership with the Leadership in CDI Boot Camp from the experts at ACDIS. Graduates of the program earn the right to call themselves ACDIS-Approved CDI Leaders. Find out more about the program by clicking here. (https://ow.ly/gWOR50P8rnm) ACDIS update: Respond to the 2023 CDI Week Industry Survey by August 2, 2023! (https://www.surveymonkey.com/r/2023-CDI-Week-Industry-Survey) Apply to speak at the 2024 ACDIS national conference, ACDIS Symposium: Outpatient CDI, or physician advisor pre-conference event by July 24! (https://app.keysurvey.com/f/41638681/52dc/) Contribute an article for the September/October 2023 edition of the CDI Journal by August 1 by emailing info@acdis.org!

The intersection of human health and agbioscience is one rarely discussed, but it is one that is delivering innovation that may save lives. Today's guest is long-time human health leader who is turning to agbioscience to develop a solution that could transform the way doctors care for patients with chronic, traumatic or surgical wounds. Andy Eibling, President and CEO of GeniPhys, joins us to talk about his journey from Eli Lilly to the leading the startup that inspires him to continue learning. He also talks about GeniPhys solving a problem that the human body cannot: producing collagen to aid the remodeling process that comes from injury, surgical wounds and more.   Andy gets into the opportunity for GeniPhys to cross into multiple verticals, how the agbiosciences help the company to source their collagen and working alongside Indiana's 5th nationally ranked pork production industry to make this a statewide success story. He also gets into GeniPhys' fundraising to date and their plans for refining the manufacturing process, adding talent to their team and what's ahead as they grow and scale. 

Producer's Note: During the summer months we'll be re-releasing some of our favorite episodes for our "Summer Encore Series." This episode originally dropped on November 12, 2019, and we loved the creative way in which IU Health immersed themselves in the patient's journey. Please note that some details and situations described in the episode may not neccessarily be the same as when it originally was released. Immersive experiences can be a powerful tool to demonstrate the customer experience, but for patients at a hospital, it can be impactful – and emotional – for the leadership of an organization. Guest host Pat Gibbons welcomes guest Karen Cernock from Indiana University Health to discuss how an immersive experience for their board developed into a program throughout the organization. Read the original episode's show notes page here: https://cxleaderpodcast.com/wear-comfortable-shoes/ Listen to more podcasts at https://cxleaderpodcast.com/ Learn more about Walker at https://walkerinfo.com/ 

Season 4 Episode 3- CAR T Therapy This week we sit down with Teresa Thakrar, PharmD, BCOP, CPP to discuss CAR T therapy. Dr. Thakrar is currently a hematology, stem cell transplant, and cellular therapy Clinical Pharmacist and Clinical Oncology Pharmacy Team Lead at Indiana University Health in Indianapolis. Prior to this role, she was a stem cell transplant Clinical Pharmacist at the University of North Carolina Medical Center in Chapel Hill, NC. Dr. Thakrar received her Doctor of Pharmacy from Purdue University College of Pharmacy. She completed a PGY1 Pharmacy Practice Residency at St. Vincent Hospital in Indianapolis and a PGY2 Oncology Pharmacy Residency at the University of North Carolina Medical Center.

Ron Stiver is the President of System Health Solutions at Indiana University Health. In this episode, you'll hear Ron tell us about how he played football at DePauw University and how football coaches have been significant mentors throughout his life, including after he was done playing, about how meeting former governor Mitch Daniels while working at Eli Lilly led to volunteering for the Daniels gubernatorial campaign, running the Department of Workforce Development, turning around the BMV, and meeting the former CEO of IU Health, and about why he is focused on making an impact that is bigger than himself. As always, don't forget to check out our partners North Indy Magazine and Synergize. Ron Stiver LinkedIn: https://www.linkedin.com/in/ron-stiver-50ba1647/ CCS Podcast Partners: North Indy Magazine: https://townepost.com/broad-ripple/ Synergize: https://synergizeindy.com/ Connect with CCS: Connect with Jason: https://www.linkedin.com/in/jason-ulm-0919123/ Connect with Drew: https://www.linkedin.com/in/drewfeutz/ Connect with Matt Hadley: https://www.linkedin.com/in/buildauthenticrelationships/ Connect with Matt Carroll: https://www.linkedin.com/in/matthewcarroll1/

When Adam Getz first joined the military, his plan was to finish his initial enlistment as an Army musician and separate. As his roles changed within the military, Adam decided to serve for 20 years with the goal of having a second career in the private sector.  Adam earned an MBA, PMP and Lean Six Sigma Green Belt certifications to prepare him for his next career in project management. When Adam left the military4/2021, he spent a year as a Senior Project Manager in pharmaceutical contract manufacturing. Today, he is a Senior Project Manager in Supply Chain Operations at Indiana University Health. Adam finished his MBA earlier in his Army career. Once he focused on becoming a project manager, he completed his PMP and Lean Six Sigma Green Belt closer to retirement. Adam used a full 24 months to prepare for his transition by attending TAP classes, leveraging LinkedIn and networking . After using The 20-Minute Networking Meeting book as a guide on how to conduct an informational interview, Adam conducted close to 100 interviews. With each conversation, Adam learned more about project management in the private sector, gained new mentors and ultimately confirmed that he did want to pursue project management. His interactions helped him to translate his Army skills to industry standard terminology. As an introvert, networking did not come naturally to Adam. At first, he felt like he was imposing on people but then realized after a few informational interviews that people are eager to help.  Adam reflects on the differences of project management between the military and the private sector. Because rank is not a factor in his current position, it's not always obvious how to get something accomplished. The job of a project manager is to lead cross-functional teams as an individual contributor and yet influence people to meet deadlines and finish projects. Building relationships and having expert knowledge are keys to being a successful project manager.Adam discusses how asking questions has earned him respect with coworkers and supervisors in his post-military roles. He learned that people are eager to help and asking questions builds teamwork, relationships and rapport. Adam encourages veterans to check their ego and stay humble. While some people will show appreciation toward a veteran, others are indifferent.When job searching, many roles do not post a salary range.  Adam discusses how his informational interviews and mentors gained through LinkedIn helped him uncover a desired salary range based on his background and skills. Adam and Lori end the podcast discussing leaving jobs in the private sector, sometimes even in the first year. While Adam acknowledges that finding a job that you are passionate about is ideal, it's not realistic for everybody. He instead encourages people to find jobs that match their skillsets and ones they enjoy in some capacity. When a job isn't right for you, it's okay to find something that is a better fit. Sometimes you have to make a change to move forward. Head over to the Lessons Learned for Vets YouTube channel at https://tinyurl.com/llforvets22 to hear a bonus clip on struggles and surprises Adam has encountered during his first 18 months out of uniform.You can connect with Adam at https://www.linkedin.com/in/adamcgetz/Explore The 20-Minute Networking Meeting book by clicking here.SUBSCRIBE & LEAVE A FIVE-STAR REVIEW and share this to other veterans who might need help as they transition from the military!

This episode Tim Tarnowski, SVP & Chief Information Officer at Indiana University Health. Here, he discusses his path to IU Health, the promise & purpose of UI Health's new innovation fund, getting back to business as the pandemic slows, and more.

Chatting with my man John Gallagher today on all things health, healthcare and leadership. John is the founder and CEO of Growing Champions, LLC where his mission is to Grow Champions that Grow Champions. Over his 25-year career, John has coached clients in Healthcare, Manufacturing, and other industries. John's work in Healthcare included Atrius Health, a large multi- specialty group practice in Boston, MA, Cone Health in Greensboro, NC, Indiana University Health, and Harvard University Health Services. John has spoken, written, blogged, coached and taught on many current Healthcare industry topics, including: Digital Health, Population Health, Cancer Care Transformation, ACO , PCMH, Primary Care, Specialty care including medical and surgical specialties, and Leadership Development. John has provided professional advisory/coaching at the C-suite, executive and director levels as well as facilitated change management through all levels of Healthcare operations. John also transformed his health and nutrition habits on his way to losing 80lbs and being featured for his efforts in Men's Health Magazine, serving as a prime example you can get fitter at any age. On top of that he is an all around good dude who truly wants to help people get healthier and happier in every area of their life. You can learn more about him here at: https://www.instagram.com/coach.johngallagher/ and https://linktr.ee/coachjohngallagher and his podcast "Uncommon Leader" is available on all major podcast outlets. Reminder our 40 Days of Fitness is Open for Enrollment - https://www.jeremyscottfitness.com/40-days-of-fitness Thanks to our Sponsors: Athletic Greens www.athleticgreens.com/jeremyscott Free year supply of vitamin D3 with 5 free travel packs Sleeves Sold Separately - https://sleevessoldseparately.com/collections/jscott Code JSCOTT15 for 15% off all clothes & gear Dry Farms Wine - dryfarmwines.com/jeremyscottfitness Each new member will earn an extra bottle for just a penny with their first order of wine when they use this link. Jaylab Pro - https://jeremyscottfitness.jaylabpro.com/products.html